Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2001 Nov 6;98(23):13288-93.
doi: 10.1073/pnas.221452198. Epub 2001 Oct 30.

Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects

Affiliations
Clinical Trial

Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects

G M Ortiz et al. Proc Natl Acad Sci U S A. .

Abstract

The risks and benefits of structured treatment interruption (STI) in HIV-1-infected subjects are not fully understood. A pilot study was performed to compare STI with continuous highly active antiretroviral therapy (HAART) in chronic HIV-1-infected subjects with HIV-1 plasma RNA levels (VL) <400 copies per ml and CD4(+) T cells >400 per microl. CD4(+) T cells, VL, HIV-1-specific neutralizing antibodies, and IFN-gamma-producing HIV-1-specific CD8(+) and CD4(+) T cells were measured in all subjects. STIs of 1-month duration separated by 1 month of HAART, before a final 3-month STI, resulted in augmented CD8(+) T cell responses in all eight STI subjects (P = 0.003), maintained while on HAART up to 22 weeks after STI, and augmented neutralization titers to autologous HIV-1 isolate in one of eight subjects. However, significant decline of CD4(+) T cell count from pre-STI level, and VL rebound to pre-HAART baseline, occurred during STI (P = 0.001 and 0.34, respectively). CD4(+) T cell counts were regained on return to HAART. Control subjects (n = 4) maintained VL <400 copies per ml and stable CD4(+) T cell counts, and showed no enhancement of antiviral CD8(+) T cell responses. Despite increases in antiviral immunity, no control of VL was observed. Future studies of STI should proceed with caution.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic presenting schedule of structured antiretroviral treatment interruptions (STI). STI subjects underwent two 4-week-long STIs and one 12-week-long STI. Control subjects remained on HAART. Gray rectangles, STI periods; White rectangles, on HAART periods.
Figure 2
Figure 2
Longitudinal follow-up of HIV-1 plasma RNA levels and CD4+ T cell levels in eight chronically HIV-1-infected individuals undergoing STI. Time of follow-up was in weeks after initiation of first treatment interruption. HIV-1 plasma RNA, and CD4+ T cell counts are presented along the left and right y axes, respectively. If measurements were available, tabs on the left and right y axes represent pre-HAART baseline for HIV-1 plasma RNA level and CD4+ T cell count, respectively. Gray rectangles, STI periods; White rectangles, on HAART periods.

Similar articles

Cited by

References

    1. Mellors J W, Rinaldo C R, Jr, Gupta P, White R M, Todd J A, Kingsley L A. Science. 1996;272:1167–1170. - PubMed
    1. O'Brien T R, Blattner W A, Waters D, Eyster E, Hilgartner M W, Cohen A R, Luban N, Hatzakis A, Aledort L M, Rosenberg P S, et al. J Am Med Assoc. 1996;276:105–110. - PubMed
    1. Borrow P, Lewicki H, Hahn B H, Shaw G M, Oldstone M B. J Virol. 1994;68:6103–6110. - PMC - PubMed
    1. Koup R A, Safrit J T, Cao Y, Andrews C A, McLeod G, Borkowsky W, Farthing C, Ho D D. J Virol. 1994;68:4650–4665. - PMC - PubMed
    1. Kalams S A, Buchbinder S P, Rosenberg E S, Billingsley J M, Colbert D S, Jones N G, Shea A K, Trocha A K, Walker B D. J Virol. 1999;73:6715–6720. - PMC - PubMed

Publication types

MeSH terms

Substances